| human | Q5 |
| P6178 | Dimensions author ID | 01152071666.19 |
| P496 | ORCID iD | 0000-0003-1395-1289 |
| P108 | employer | World Health Organization | Q7817 |
| P734 | family name | Reeder | Q16881975 |
| Reeder | Q16881975 | ||
| Reeder | Q16881975 | ||
| P735 | given name | John | Q4925477 |
| John | Q4925477 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q57272236 | 'Because it is a joyful thing to carry a baby': involving men in reproductive, maternal and newborn health in East New Britain, Papua New Guinea |
| Q34874306 | A changing model for developing health products for poverty-related infectious diseases |
| Q35122417 | A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria |
| Q57272275 | A quality assurance for rural laboratories: a report on a trial distribution in Momase Region, Papua New Guinea |
| Q37649809 | A review of the current state of malaria among pregnant women in Papua New Guinea |
| Q48004030 | A simple method for typing Plasmodium falciparum merozoite surface antigens 1 and 2 (MSA-1 and MSA-2) using a dimorphic-form specific polymerase chain reaction |
| Q48021609 | A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria |
| Q44773783 | Ability of Plasmodium falciparum to invade Southeast Asian ovalocytes varies between parasite lines |
| Q57230533 | Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei |
| Q34429002 | Adhesion of Plasmodium falciparum-infected red blood cells to CD36 under flow is enhanced by the cerebral malaria-protective trait South-East Asian ovalocytosis |
| Q33558449 | Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. |
| Q47915480 | Alterations in Plasmodium falciparum genotypes during sequential infections suggest the presence of strain specific immunity. |
| Q40488611 | Analysis of serum and cerebrospinal fluid cytokine levels in subacute sclerosing panencephalitis in Papua New Guinea |
| Q36368911 | Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. |
| Q46337040 | Antibodies among men and children to placental-binding Plasmodium falciparum-infected erythrocytes that express var2csa. |
| Q40918892 | Antigenic variation and immune evasion in Plasmodium falciparum malaria |
| Q34874760 | Applied research for better disease prevention and control |
| Q57272241 | Are we really that good at treating tuberculosis? |
| Q34509744 | Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea |
| Q30382118 | Building Global Capacity for Conducting Operational Research Using the SORT IT Model: Where and Who? |
| Q30062096 | Building coherence and synergy among global health initiatives |
| Q42563731 | Building research and development on poverty-related diseases |
| Q47574854 | Caregivers' acceptance of using artesunate suppositories for treating childhood malaria in Papua New Guinea. |
| Q37058594 | Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. |
| Q35571430 | Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries? |
| Q36365076 | Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected erythrocytes |
| Q39333525 | Comment on: Promotion of malaria home-based treatment in Africa: the dangers of creating a second health system |
| Q37267964 | Comparison of three-compartment Petri dishes and individual plates for routine culture of vaginal swabs |
| Q47936295 | Complex patterns of malaria epidemiology in the highlands region of Papua New Guinea. |
| Q33521214 | Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum |
| Q46004610 | Correction: Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial. |
| Q33859217 | Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmission |
| Q46958371 | Diversity of Plasmodium falciparum vaccine candidate merozoite surface protein 4 (MSP4) in a natural population |
| Q41456213 | Diversity of agglutinating phenotype, cytoadherence, and rosette-forming characteristics of Plasmodium falciparum isolates from Papua New Guinean children. |
| Q39049364 | Does research make a difference to public health? Time for scientific journals to cross the Rubicon |
| Q39446255 | Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea |
| Q26765026 | Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies |
| Q47930441 | Engaging the community in research: lessons learned from the malaria vaccine trial |
| Q46852111 | Epidemic malaria in the highlands of Papua New Guinea. |
| Q46218708 | Epidemiology of malaria in the Papua New Guinean highlands |
| Q47862563 | Evidence for vesicle-mediated trafficking of parasite proteins to the host cell cytosol and erythrocyte surface membrane in Plasmodium falciparum infected erythrocytes |
| Q41928687 | Evidence that recurrent Plasmodium falciparum infection is caused by recrudescence of resistant parasites |
| Q57272217 | Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios |
| Q24632119 | Genome-wide and fine-resolution association analysis of malaria in West Africa |
| Q39730124 | Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. |
| Q35037036 | Global Population Structure of the Genes Encoding the Malaria Vaccine Candidate, Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1). |
| Q38425174 | Glycophorin C delta(exon3) is not associated with protection against severe anaemia in Papua New Guinea. |
| Q43773323 | Haptoglobin levels are associated with haptoglobin genotype and alpha+ -Thalassemia in a malaria-endemic area. |
| Q44151265 | Health research in Papua New Guinea |
| Q37107966 | High genetic diversity of Plasmodium vivax on the north coast of Papua New Guinea |
| Q36743853 | High levels of genetic diversity of Plasmodium falciparum populations in Papua New Guinea despite variable infection prevalence |
| Q37864335 | High prevalence of sexually transmitted infections among female sex workers in the eastern highlands province of Papua New Guinea: correlates and recommendations |
| Q48004206 | Human cerebral malaria: lack of significant association between erythrocyte rosetting and disease severity |
| Q48036753 | Humoral response to defined Plasmodium falciparum antigens in cerebral and uncomplicated malaria and their relationship to parasite genotype. |
| Q33596242 | Identification of glycosaminoglycan binding domains in Plasmodium falciparum erythrocyte membrane protein 1 of a chondroitin sulfate A-adherent parasite |
| Q54302913 | Identification, and susceptibility to seven antimicrobial agents, of 61 gram-negative anaerobic rods from periodontal pockets. |
| Q28355362 | Implications of Plasmodium vivax Biology for Control, Elimination, and Research |
| Q47574439 | Improved detection of Candida albicans in a blood-culture model. |
| Q34973806 | In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs |
| Q39695196 | Increasing genetic diversity of Salmonella enterica serovar typhi isolates from papua new guinea over the period from 1992 to 1999. |
| Q37195525 | Indifferent streptococci in normal and purulent eyes of neonates |
| Q38440250 | Insight into the early spread of chloroquine-resistant Plasmodium falciparum infections in Papua New Guinea |
| Q28481649 | Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial |
| Q97689478 | Investing in Operational Research Capacity Building for Front-Line Health Workers Strengthens Countries' Resilience to Tackling the COVID-19 Pandemic |
| Q47986745 | John C Reeder--Director of the Papua New Guinea Institute of Medical Research. Interview by Pam Das. |
| Q48023236 | Lack of associations of α(+)-thalassemia with the risk of Plasmodium falciparum and Plasmodium vivax infection and disease in a cohort of children aged 3-21 months from Papua New Guinea |
| Q39069836 | Lack of multiple copies of pfmdr1 gene in Papua New Guinea |
| Q57272219 | Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccination on nasopharyngeal carriage of in Papua New Guinean children: A randomized controlled trial |
| Q39214868 | Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. |
| Q39094002 | Low prevalence of an acute phase response in asymptomatic children from a malaria-endemic area of Papua New Guinea. |
| Q39278353 | Malaria control in Papua New Guinea results in complex epidemiological changes. |
| Q57272262 | Malaria vaccines |
| Q39912283 | Measles in Papua New Guinea: an age-specific serological survey |
| Q35720069 | Microsatellite polymorphism within pfcrt provides evidence of continuing evolution of chloroquine-resistant alleles in Papua New Guinea |
| Q41914327 | Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. |
| Q31150710 | Molecular epidemiology of Plasmodium falciparum resistance to antimalarial drugs in Indonesia. |
| Q39214852 | Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. |
| Q46355824 | More, but not better |
| Q34408419 | Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission |
| Q38300351 | Multiple var gene transcripts are expressed in Plasmodium falciparum infected erythrocytes selected for adhesion. |
| Q40484288 | Muscle cell injury, haemolysis and dark urine in children with falciparum malaria in Papua New Guinea |
| Q30984906 | Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia |
| Q101145262 | Nationalizing Operational Research Capacity Building: Necessity or Luxury? |
| Q62486011 | Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line |
| Q42717074 | Neisseria gonorrhoeae isolates from four centres in Papua New Guinea remain susceptible to amoxycillin-clavulanate therapy |
| Q30967506 | New haplotypes of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene among chloroquine-resistant parasite isolates. |
| Q31143848 | Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system |
| Q30488364 | Open access for operational research publications from low- and middle-income countries: who pays? |
| Q57272256 | Papua New Guinea: targeting research to things that matter |
| Q34292107 | Parasite adhesion and immune evasion in placental malaria. |
| Q41613360 | Phylogeography of var gene repertoires reveals fine-scale geospatial clustering of Plasmodium falciparum populations in a highly endemic area |
| Q34596548 | Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea |
| Q34163026 | Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations |
| Q34100761 | Plasmodium falciparum erythrocyte membrane protein 1 functions as a ligand for P-selectin. |
| Q33645352 | Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance |
| Q46629901 | Plasmodium falciparum: distribution of msp2 genotypes among symptomatic and asymptomatic individuals from the Wosera region of Papua New Guinea |
| Q21032489 | Plasmodium malariae and Plasmodium ovale--the "bashful" malaria parasites |
| Q33344896 | Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea |
| Q35432096 | Plasmodium vivax populations are more genetically diverse and less structured than sympatric Plasmodium falciparum populations |
| Q46340740 | Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea |
| Q44161929 | Polymerase chain reaction diagnosis and the changing pattern of vector ecology and malaria transmission dynamics in papua new Guinea |
| Q35038643 | Population genetic analysis of the Plasmodium falciparum 6-cys protein Pf38 in Papua New Guinea reveals domain-specific balancing selection |
| Q33535802 | Population hemoglobin mean and anemia prevalence in Papua New Guinea: new metrics for defining malaria endemicity? |
| Q122749728 | Quality, Equity and Partnerships in Mixed Methods and Qualitative Research during Seven Years of Implementing the Structured Operational Research and Training Initiative in 18 Countries |
| Q101561861 | Quality, Equity and Utility of Observational Studies during 10 Years of Implementing the Structured Operational Research and Training Initiative in 72 Countries |
| Q40301443 | Rapid diagnostic test-based management of malaria: an effectiveness study in Papua New Guinean infants with Plasmodium falciparum and Plasmodium vivax malaria |
| Q35690828 | Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes |
| Q28483318 | Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study |
| Q46838126 | Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study |
| Q40599557 | Regulation of antigenic variation in Plasmodium falciparum: censoring freedom of expression? |
| Q38870600 | Renewed push to strengthen vector control globally |
| Q43684264 | Research for universal health coverage |
| Q39224921 | Research priorities for elimination of visceral leishmaniasis |
| Q50616124 | Research to policy and practice change: is capacity building in operational research delivering the goods? |
| Q28217640 | Restricted polymorphisms of the mannose-binding lectin gene in a population of Papua New Guinea |
| Q28469083 | Rifampicin/Cotrimoxazole/Isoniazid versus mefloquine or quinine + sulfadoxine- pyrimethamine for malaria: a randomized trial |
| Q42288806 | Rubella control in Papua New Guinea: age-specific immunity informs strategies for introduction of rubella vaccine |
| Q34602513 | Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial |
| Q48046934 | Sequence diversity and molecular evolution of the merozoite surface antigen 2 of Plasmodium falciparum |
| Q36144097 | Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea |
| Q30038747 | Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum-infected erythrocyte surface |
| Q35013867 | Southeast Asian ovalocytosis is associated with increased expression of Duffy antigen receptor for chemokines (DARC). |
| Q96764384 | Strengthening the core health research capacity of national health systems helps build country resilience to epidemics: a cross-sectional survey |
| Q35828587 | Streptococcus pneumoniae and Haemophilus influenzae in paediatric meningitis patients at Goroka General Hospital, Papua New Guinea: serotype distribution and antimicrobial susceptibility in the pre-vaccine era. |
| Q44962232 | Sulfated glycoconjugates as disrupters of Plasmodium falciparum erythrocyte rosettes. |
| Q39389471 | TDR: (back) making a difference |
| Q57272234 | TDR: a time to live |
| Q34422119 | Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. |
| Q30039199 | Targeted mutagenesis of Plasmodium falciparum erythrocyte membrane protein 3 (PfEMP3) disrupts cytoadherence of malaria-infected red blood cells |
| Q35962613 | The Structured Operational Research and Training Initiative for public health programmes |
| Q36339851 | The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. |
| Q36864588 | The age-specific prevalence of Plasmodium falciparum in migrants to Irian Jaya is not attributable to agglutinating antibody repertoire |
| Q53818014 | The development of rural laboratory services in Papua New Guinea. |
| Q48023584 | The epidemiology of malaria in the Papua New Guinea highlands: 1. Western Highlands Province |
| Q46366235 | The epidemiology of malaria in the Papua New Guinea highlands: 2. Eastern Highlands Province |
| Q43408107 | The epidemiology of malaria in the Papua New Guinea highlands: 3. Simbu Province |
| Q43505377 | The epidemiology of malaria in the Papua New Guinea highlands: 4. Enga Province |
| Q40440677 | The epidemiology of malaria in the Papua New Guinea highlands: 5. Aseki, Menyamya and Wau-Bulolo, Morobe Province. |
| Q46865284 | The epidemiology of malaria in the Papua New Guinea highlands: 6. Simbai and Bundi, Madang Province. |
| Q44137361 | The epidemiology of malaria in the Papua New Guinea highlands: 7. Southern Highlands Province |
| Q30363248 | The heterosexual HIV type 1 epidemic in Papua New Guinea is dominated by subtype C. |
| Q35150337 | The malaria vaccine development program in Papua New Guinea |
| Q30384988 | The need for operational research and capacity-building in support of the Global Technical Strategy for Malaria 2016-2030. |
| Q47919482 | The population structure of Plasmodium falciparum and Plasmodium vivax during an epidemic of malaria in the Eastern Highlands of Papua New Guinea. |
| Q37088901 | The risk of malarial infections and disease in Papua New Guinean children. |
| Q42912553 | The sensitivity of the OptiMAL rapid diagnostic test to the presence of Plasmodium falciparum gametocytes compromises its ability to monitor treatment outcomes in an area of Papua New Guinea in which malaria is endemic |
| Q36649305 | The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea |
| Q34990240 | Towards a malaria vaccine for Papua New Guinea. |
| Q30828703 | Transcription of multiple var genes by individual, trophozoite-stage Plasmodium falciparum cells expressing a chondroitin sulphate A binding phenotype |
| Q17485678 | Understanding the population genetics of Plasmodium vivax is essential for malaria control and elimination |
| Q34874787 | What have we learned from 40 years of supporting research and capacity building? |
| Q93103962 | What if communities held the solutions for universal health coverage? |
| Q43894289 | World Malaria Day 2014: invest in the future. Defeat malaria |
Search more.